Cost-utility analysis of tislelizumab monotherapy for second-line treatment of advanced or metastatic esophageal squamous cell carcinoma

WEN Enhui; GAO Chuan; DONG Juanni; LONG Lihui; RONG Biaoxue

doi:10.6039/j.issn.1001-0408.2023.05.13

您当前的位置：

首页 >

文章列表页 >

Cost-utility analysis of tislelizumab monotherapy for second-line treatment of advanced or metastatic esophageal squamous cell carcinoma

更新时间：2025-09-27

- Cost-utility analysis of tislelizumab monotherapy for second-line treatment of advanced or metastatic esophageal squamous cell carcinoma
- ZHONGGUO YAOFANG Vol. 34, Issue 5, Pages: 581-586(2023)
- 作者机构：
  
  1.西安医学院第一附属医院临床药学室，西安　710077
  2.西安医学院第一附属医院肿瘤科，西安　710077
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.05.13
  CLC： R956;R979.1
- Received：29 August 2022，
  
  Revised：2023-02-02，
  
  Published：15 March 2023
- 稿件说明：
移动端阅览
文恩辉,高川,董娟妮,等.替雷利珠单抗单药二线治疗晚期或转移性食管鳞状细胞癌的成本-效用分析[J].中国药房,2023,34(05):581-586.

WEN Enhui,GAO Chuan,DONG Juanni,et al.Cost-utility analysis of tislelizumab monotherapy for second-line treatment of advanced or metastatic esophageal squamous cell carcinoma[J].ZHONGGUO YAOFANG,2023,34(05):581-586.
文恩辉,高川,董娟妮,等.替雷利珠单抗单药二线治疗晚期或转移性食管鳞状细胞癌的成本-效用分析[J].中国药房,2023,34(05):581-586. DOI： 10.6039/j.issn.1001-0408.2023.05.13.

WEN Enhui,GAO Chuan,DONG Juanni,et al.Cost-utility analysis of tislelizumab monotherapy for second-line treatment of advanced or metastatic esophageal squamous cell carcinoma[J].ZHONGGUO YAOFANG,2023,34(05):581-586. DOI： 10.6039/j.issn.1001-0408.2023.05.13.

摘要

目的

评价替雷利珠单抗单药二线治疗晚期或转移性食管鳞状细胞癌（ESCC）的经济性，为临床合理用药提供参考。

方法

从我国卫生体系角度出发，基于RATIONALE-302研究数据构建三状态分区生存模型，模拟时限为10年，循环周期为1个月。采用成本-效用分析法，以质量调整生命年（QALY）作为效用指标并计算增量成本-效果比（ICER），比较替雷利珠单抗单药方案相对于化疗方案二线治疗晚期或转移性ESCC的经济性。采用敏感性分析和情境分析来验证基础分析结果的稳健性。

结果

基础分析结果显示，相对于化疗组，替雷利珠单抗组患者的人均增量成本为35 025.32元，人均增量效果为0.23 QALYs，ICER为154 707.71元/QALY，远低于以3倍2021年我国人均国内生产总值（GDP）即242 928元作为的意愿支付（WTP）阈值。单因素敏感性分析结果显示，阿帕替尼成本、疾病进展状态效用值和化疗组不良反应处理成本等参数对ICER值的影响较大，但这些参数均不能导致基础分析结果翻转。概率敏感性分析结果显示，当WTP阈值为242 928元/QALY时，替雷利珠单抗单药方案具有经济性的概率为81％。情境分析结果显示，当模型模拟时限分别为5年和20年时，替雷利珠单抗单药方案的ICER值分别为99 973.60元/QALY和155 773.22元/QALY，均未超过以3倍2021年我国人均GDP作为的WTP阈值。

结论

当以3倍2021年我国人均GDP作为WTP阈值时，相较于化疗方案，替雷利珠单抗单药方案二线治疗晚期或转移性ESCC更具有经济性。

Abstract

OBJECTIVE

To evaluate the cost-effectiveness of tislelizumab monotherapy in the second-line treatment of advanced or metastatic esophageal squamous cell carcinoma （ESCC），so as to provide reference for rational use of drug in clinic.

METHODS

A three-state partitioned survival model was constructed from the perspective of China’s health system， based on the data of RATIONALE-302 study，with simulation time limit of 10 years， cycle period of 1 month. The incremental cost-effectiveness ratio （ICER） was calculated with quality-adjusted life year （QALY） as utility index. The cost-effectiveness of tislelizumab monotherapy was compared with that of chemotherapy for second-line treatment of advanced or metastatic ESCC by cost-utility analysis. The stability of basic analysis results was validated through sensitivity analysis and scenario analysis.

RESULTS

The results of basic analysis showed that compared with chemotherapy group， incremental cost per capita of tislelizumab group was 35 025.32 yuan，and incremental utility per capita was 0.23 QALYs； ICER was 154 707.71 yuan/QALY， which was far lower than the willingness-to-pay （WTP） threshold of 3 times of China’s per capita gross domestic product （GDP） 242 928 yuan in 2021. The results of univariate sensitivity analysis showed that parameters such as the cost of apatinib， the utility value of disease progression status and the cost of adverse reactions in the chemotherapy group had a great impact on the ICER value， but these parameters could not cause the reversal of the basic analysis results. Probabilistic sensitivity analysis showed that WTP threshold was 242 928 yuan/QALY，the probability of tislelizumab monotherapy possessed cost-effectiveness was 81%. Results of scenario analysis showed that in which model simulation time lasted for 5 or 20 years，ICER of tislelizumab was 99 973.60 yuan/QALY and 155 773.22 yuan/QALY， which were less than 3 times of China’s per capita GDP in 2021 as WTP threshold.

CONCLUSIONS

When three times of China’s GDP per capita in 2021 is taken as the WTP threshold， the second-line treatment of tirelizumab monotherapy for advanced or metastatic ESCC is more cost-effective than chemotherapy.

关键词

Keywords

references

SUNG H ， FERLAY J ， SIEGEL R L ， et al . Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2021 ， 71 （ 3 ）： 209 - 249 .

国家卫生健康委办公厅 . 食管癌诊疗指南：2022年版 [EB/OL ] . [ 2022-04-03 ] . http：//www.nhc.gov.cn/yzygj/s7659/202204/a0e67177df1f439898683e1333957c74.shtml http://www.nhc.gov.cn/yzygj/s7659/202204/a0e67177df1f439898683e1333957c74.shtml .

AN L ， ZHENG R S ， ZENG H M ， et al . The survival of esophageal cancer by subtype in China with comparison to the United States [J ] . Int J Cancer ， 2023 ， 152 （ 2 ）： 151 - 161 .

齐冉，杜桂平，刘旭婷，等 . 帕博利珠单抗联合化疗一线治疗晚期或转移性食管癌的成本-效用分析 [J ] . 中国药房， 2022 ， 33 （ 12 ）： 1466 - 1473 .

SHEN L ， KATO K ， KIM S B ， et al . Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma （RATIONALE-302）：a randomized phase Ⅲ study [J ] . J Clin Oncol ， 2022 ， 40 （ 26 ）： 3065 - 3076 .

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会（CSCO）食管癌诊疗指南2022 [M ] . 北京：人民卫生出版社， 2022 ： 75 - 83 .

刘国恩 . 中国药物经济学评价指南2020 [M ] . 北京：中国市场出版社， 2020 ： 13 - 26 .

曾小慧，彭六保，谭重庆，等 . 药物经济学评价中的分区生存模型 [J ] . 中国新药与临床杂志， 2020 ， 39 （ 8 ）： 504 - 507 .

胡梦雪，高红婷，宁智鹏，等 . 帕博利珠单抗单药与化疗二线治疗晚期或转移性食管癌的成本-效果分析 [J ] . 中国医院药学杂志， 2022 ， 42 （ 3 ）： 318 - 323 .

石丰豪，金敏，王子婧，等 . 卡瑞利珠单抗对比化疗方案二线治疗晚期或转移性食管鳞状细胞癌的成本效用分析 [J ] . 中国卫生经济， 2021 ， 40 （ 12 ）： 73 - 77 .

LIN Y T ， CHEN Y ， LIU T X ， et al . Cost-effectiveness analysis of camrelizumab immunotherapy versus docetaxel or irinotecan chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma [J ] . Cancer Manag Res ， 2021 ， 13 ： 8219 - 8230 .

YANG F ， FU Y ， KUMAR A ， et al . Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China [J ] . Ann Transl Med ， 2021 ， 9 （ 15 ）： 1226 .

LIN Y T ， LIU T X ， CHEN J ， et al . Cost-effectiveness of nivolumab immunotherapy vs. paclitaxel or docetaxel chemotherapy as second-line therapy in advanced esophageal squamous cell carcinoma in China [J ] . Front Public Health ， 2022 ， 10 ： 923619 .

ZHANG P F ， XIE D ， LI Q . Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma [J ] . Future Oncol ， 2020 ， 16 （ 17 ）： 1189 - 1198 .

国家统计局 . 中华人民共和国2021年国民经济和社会发展统计公报 [J ] . 中国统计， 2022 （ 3 ）： 9 - 26 .

孟蕊，芮明军，王欣恬，等 . 不同决策分析模型在抗肿瘤药物经济学评价中的应用：以加拿大CADTH为例 [J ] . 中国药房， 2021 ， 32 （ 14 ）： 1752 - 1757 .

WU B ， YE M ， CHEN H F ， et al . Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer：an economic evaluation in the Chinese context [J ] . Clin Ther ， 2012 ， 34 （ 2 ）： 468 - 479 .

Views

238

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pharmacoeconomic evaluation of durvalumab combined with chemotherapy as first-line therapy for advanced biliary tract cancer

Pharmacoeconomic evaluation of trastuzumab biosimilars versus original drug in the treatment of recurrent/metastatic HER-2 positive breast cancer

Cost-utility analysis of capecitabine metronomic chemotherapy combined with aromatase inhibitor as first-line treatment for HR+/HER2－ metastatic breast cancer

Pharmacoeconomic evaluation of finerenone combined with standard regimen in the treatment of heart failure with preserved or mildly reduced ejection fraction

Cost-utility analysis of tislelizumab in the treatment of locally advanced or metastatic （non-）squamous NSCLC

Related Author

HUO Liman

DUAN Yangyang

LIANG Ping

SHAN Bin

SUN Xiaoli

FENG Rui

LIU Tong

TENG Xue

Related Institution

School of Health Emergency Management， Tianjin University

School of Pharmacy， Hebei Medical University

Dept. of Pharmacy， the Fourth Hospital of Hebei Medical University

Dept. of Pharmacy， Harbin Medical University Cancer Hospital

Hebei Society for Integrated Drug and Health Technology Assessment

⁰